531 results on '"Casanova, Ciro"'
Search Results
102. Gender and COPD in Patients With Chronic Respiratory Insufficiency Requiring Domiciliary Oxygen Therapy
- Author
-
de Torres, Juan P., Casanova, Ciro, and Celli, Bartolome R.
- Published
- 2006
103. Gender and Chronic Obstructive Pulmonary Disease in High-Risk Smokers
- Author
-
de Torres, Juan P., Campo, Arantza, Casanova, Ciro, Aguirre-Jaime, Armando, and Zulueta, Javier
- Published
- 2006
- Full Text
- View/download PDF
104. Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease
- Author
-
Casanova, Ciro, Cote, Claudia, de Torres, Juan P., Aguirre-Jaime, Armando, Marin, Jose M., Pinto-Plata, Victor, and Celli, Bartolome R.
- Published
- 2005
- Full Text
- View/download PDF
105. A Meta-analysis of Nocturnal Noninvasive Positive Pressure Ventilation in Patients With Stable COPD*
- Author
-
Wijkstra, Peter J., Lacasse, Yves, Guyatt, Gordon H., Casanova, Ciro, Gay, Peter C., Jones, Jeffry Meecham, and Goldstein, Roger S.
- Published
- 2003
106. Prognostic assessment in COPD without lung function: the B-AE-D indices
- Author
-
Boeck, Lucas, Soriano, Joan B., Brusse-Keizer, Marjolein, Blasi, Francesco, Kostikas, Konstantinos, Boersma, Wim, Milenkovic, Branislava, Louis, Renaud, Lacoma, Alicia, Djamin, Remco, Aerts, Joachim, Torres, Antoni, Rohde, Gernot, Welte, Tobias, Martinez-Camblor, Pablo, Rakic, Janko, Scherr, Andreas, Koller, Michael, van der Palen, Job, Marin, Jose M., Alfageme, Inmaculada, Almagro, Pere, Casanova, Ciro, Esteban, Cristobal, Soler-Cataluña, Juan J., de-Torres, Juan P., Miravitlles, Marc, Celli, Bartolome R., Tamm, Michael, Stolz, Daiana, Universitat Autònoma de Barcelona, Pulmonologie, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, MUMC+: MA Med Staf Spec Longziekten (9), and Faculty of Behavioural, Management and Social Sciences
- Subjects
Male ,Exacerbation ,Severity of Illness Index ,Body Mass Index ,Pulmonary Disease, Chronic Obstructive ,0302 clinical medicine ,Forced Expiratory Volume ,030212 general & internal medicine ,Longitudinal Studies ,Lung ,2. Zero hunger ,COPD ,medicine.diagnostic_test ,Glycopeptides ,Middle Aged ,Prognosis ,3. Good health ,Respiratory Function Tests ,Treatment Outcome ,Cardiology ,Female ,METIS-318027 ,Risk assessment ,Pulmonary and Respiratory Medicine ,Spirometry ,medicine.medical_specialty ,Risk Assessment ,External validity ,03 medical and health sciences ,Copeptin ,Internal medicine ,Severity of illness ,medicine ,Humans ,Mortality ,Exercise ,Aged ,Inflammation ,business.industry ,Reproducibility of Results ,medicine.disease ,respiratory tract diseases ,Oxygen ,Dyspnea ,030228 respiratory system ,Physical therapy ,IR-101435 ,business ,Body mass index - Abstract
Altres ajuts: A. Schötzau performed data management of PROMISE for which he received financial compensation.Thermo Scientific Biomarkers (Hennigsdorf, Germany) provided all the reagents for copeptin measurements. Several composite markers have been proposed for risk assessment in chronic obstructive pulmonary disease (COPD). However, choice of parameters and score complexity restrict clinical applicability. Our aim was to provide and validate a simplified COPD risk index independent of lung function. The PROMISE study (n=530) was used to develop a novel prognostic index. Index performance was assessed regarding 2-year COPD-related mortality and all-cause mortality. External validity was tested in stable and exacerbated COPD patients in the ProCOLD, COCOMICS and COMIC cohorts (total n=2988). Using a mixed clinical and statistical approach, body mass index (B), severe acute exacerbations of COPD frequency (AE), modified Medical Research Council dyspnoea severity (D) and copeptin (C) were identified as the most suitable simplified marker combination. 0, 1 or 2 points were assigned to each parameter and totalled to B-AE-D or B-AE-D-C. It was observed that B-AE-D and B-AE-D-C were at least as good as BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity), ADO (age, dyspnoea, airflow obstruction) and DOSE (dyspnoea, obstruction, smoking, exacerbation) indices for predicting 2-year all-cause mortality (c-statistic: 0.74, 0.77, 0.69, 0.72 and 0.63, respectively; Hosmer-Lemeshow test all p>0.05). Both indices were COPD specific (c-statistic for predicting COPD-related 2-year mortality: 0.87 and 0.89, respectively). External validation of B-AE-D was performed in COCOMICS and COMIC (c-statistic for 1-year all-cause mortality: 0.68 and 0.74; c-statistic for 2-year all-cause mortality: 0.65 and 0.67; Hosmer-Lemeshow test all p>0.05). The B-AE-D index, plus copeptin if available, allows a simple and accurate assessment of COPD-related risk. The B-AE-D indices allow a simple and accurate assessment of COPD-related risk in the absence of lung function
- Published
- 2016
107. Long-term Controlled Trial of Nocturnal Nasal Positive Pressure Ventilation in Patients With Severe COPD*
- Author
-
Casanova, Ciro, Celli, Bartolome R., Tost, Lina, Soriano, Estanislao, Abreu, Juan, Velasco, Valle, and Santolaria, Francisco
- Published
- 2000
108. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD
- Author
-
Pinto-Plata Victor, Casanova Ciro, Müllerova Hana, de Torres Juan P, Corado Henneth, Varo Nerea, Cordoba Elizabeth, Zeineldine Salah, Paz Hildegarde, Baz Rebeca, Divo Miguel, Cortopassi Felipe, and Celli Bartolome R
- Subjects
Exercise ,Inflammation ,Phenotypes ,Repair ,Survival ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background The relationship between serum biomarkers and clinical expressions of COPD is limited. We planned to further describe this association using markers of inflammation and injury and repair. Methods We studied lung function, comorbidities, exercise tolerance, BODE index, and quality of life in 253 COPD patients and recorded mortality over three years. Serum levels of Interleukins 6,8 and16, tumor necrosis factor alpha (TNF α) [inflammatory panel], vascular endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP-9) [injury and repair panel] and pulmonary and activation-regulated chemokine (PARC/CCL-18) and monocyte chemotactic protein 1 (MCP-1/CCL2) [chemoattractant panel] were measured. We related the pattern of the biomarker levels to minimal clinically important differences (MCID) using a novel visualization method [ObServed Clinical Association Results (OSCAR) plot]. Results Levels of the inflammatory markers IL-6, TNF α were higher and those of injury and repair lower (p Conclusions In COPD, serum biomarkers of inflammation and repair are distinctly associated with important clinical parameters and survival.
- Published
- 2012
- Full Text
- View/download PDF
109. Additional file 1: of Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease
- Author
-
Guerra, Beniamino, Haile, Sarah, Lamprecht, Bernd, Ramírez, Ana, Martinez-Camblor, Pablo, Kaiser, Bernhard, Alfageme, Inmaculada, Almagro, Pere, Casanova, Ciro, Esteban-González, Cristóbal, Soler-Cataluña, Juan, De-Torres, Juan, Miravitlles, Marc, Bartolome Celli, Marin, Jose, Riet, Gerben Ter, Sobradillo, Patricia, Lange, Peter, Garcia-Aymerich, Judith, Antó, Josep, Turner, Alice, Meilan Han, Langhammer, Arnulf, Leivseth, Linda, Bakke, Per, Johannessen, Ane, Oga, Toru, Cosio, Borja, Ancochea-Bermúdez, Julio, Echazarreta, Andres, Roche, Nicolas, Pierre-Régis Burgel, Sin, Don, Soriano, Joan, and Puhan, Milo
- Abstract
The Appendix. (DOCX 90 kb)
- Published
- 2018
- Full Text
- View/download PDF
110. Late Breaking Abstract - A New study of the Prevalence of COPD in Spain: EPISCAN II
- Author
-
Soriano, Joan Bautista, primary, Alfageme, Inmaculada, additional, Miravitlles, Marc, additional, De Lucas, Pilar, additional, Soler-Cataluña, Juan José, additional, García-Río, Francisco, additional, Casanova, Ciro, additional, Rodríguez González-Moro, José Miguel, additional, Cosío, Borja G, additional, Sánchez, Guadalupe, additional, and Ancochea, Julio, additional
- Published
- 2019
- Full Text
- View/download PDF
111. TNFA-863 polymorphism is associated with a reduced risk of Chronic Obstructive Pulmonary Disease: A replication study
- Author
-
Medina-Coello Chaxiraxi, Varo Nerea, Maca-Meyer Nicole, Rodríguez-Pérez María C, de-Torres Juan P, Baz-Dávila Rebeca, Córdoba-Lanús Elizabeth, Aguirre-Jaime Armando, and Casanova Ciro
- Subjects
Internal medicine ,RC31-1245 ,Genetics ,QH426-470 - Abstract
Background TNF-α mediated inflammation is thought to play a key role in the respiratory and systemic features of Chronic Obstructive Pulmonary Disease. The aim of the present study was to replicate and extend recent findings in Taiwanese and Caucasian populations of associations between COPD susceptibility and variants of the TNFA gene in a Spanish cohort. Methods The 3 reported SNPs were complemented with nine tag single nucleotide polymorphisms (SNP) of the TNFA and LTA genes and genotyped in 724 individuals (202 COPD patients, 90 smokers without COPD and 432 healthy controls). Pulmonary function parameters and serum inflammatory markers were also measured in COPD patients. Results The TNFA rs1800630 (-863C/A) SNP was associated with a lower COPD susceptibility (ORadj = 0.50, 95% CI = 0.33-0.77, p = 0.001). The -863A allele was also associated with less severe forms of the disease (GOLD stages I and II) (ORadj = 0.303, 95%CI = 0.14-0.65, p = 0.014) and with lower scores of the BODE index (< 2) (ORadj = 0.40, 95%CI = 0.17-0.94, p = 0.037). Moreover, the -863A carrier genotype was associated with a better FEV1 percent predicted (p = 0.004) and a lower BODE index (p = 0.003) over a 2 yrs follow-up period. None of the TNFA or LTA gene variants correlated with the serum inflammatory markers in COPD patients (p > 0.05). Conclusions We replicated the previously reported association between the TNFA -863 SNP and COPD. TNFA -863A allele may confer a protective effect to the susceptibility to the disease in the Spanish population.
- Published
- 2011
- Full Text
- View/download PDF
112. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort.
- Author
-
Calle Rubio, Myriam, Rodriguez Hermosa, Juan Luis, de Torres, Juan P., Marín, José María, Martínez-González, Cristina, Fuster, Antonia, Cosío, Borja G., Peces-Barba, Germán, Solanes, Ingrid, Feu-Collado, Nuria, Lopez-Campos, Jose Luis, Casanova, Ciro, and CHAIN Study Investigators
- Subjects
OBSTRUCTIVE lung diseases ,QUALITY of life - Abstract
Background: Control in COPD is a dynamic concept that can reflect changes in patients' clinical status that may have prognostic implications, but there is no information about changes in control status and its long-term consequences.Methods: We classified 798 patients with COPD from the CHAIN cohort as controlled/uncontrolled at baseline and over 5 years. We describe the changes in control status in patients over long-term follow-up and analyze the factors that were associated with longitudinal control patterns and related survival using the Cox hazard analysis.Results: 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 (52.1%) changed control status during follow-up. The variables significantly associated with persistent control were not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All-cause mortality was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all-cause mortality was 2.274 (95% CI 1.394-3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow-up period, 20% had scaled up their treatment, with triple therapy being the most frequent therapeutic pattern.Conclusions: The evaluation of COPD control status provides relevant prognostic information on survival. There is important variability in clinical control status and only a small proportion of the patients had persistently good control. Changes in the treatment pattern may be relevant in the longitudinal pattern of COPD clinical control. Further studies in other populations should validate our results.Trial Registration: Clinical Trials.gov: identifier NCT01122758. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
113. Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease
- Author
-
Aguirre-Jaime Armando, Montejo de Garcini Angela, Casanova Ciro, de Torres Juan P, and Celli Bartolome R
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Rationale We had shown that COPD women expressed more dyspnea than men for the same degree of airway obstruction. Objectives Evaluate gender differences in respiratory factors associated with dyspnea in COPD patients. Methods In a FEV1 % matched population of 100 men and women with COPD we measured: age, MMRC, FEV1, FVC, TLC, IC/TLC, PaO2, PaCO2, DLCO, Pimax, P0.1, Ti/Ttot, BMI, ffmi, 6MWD and VAS scale before and after the test, the Charlson score and the SGRQ. We estimated the association between these parameters and MMRC scores. Multivariate analysis determined the independent strength of those associations. Results MMRC correlated with: BMI (men:-0.29, p = 0.04; women:-0.28, p = 0.05), ffmi (men:-0.39, p = 0.01), FEV1 % (men:-0.64, p < 0.001; women:-0.29, p = 0.04), FVC % (men:-0.45, p = 0.001; women:-0.33, p = 0.02), IC/TLC (men:-0.52, p < 0.001; women: -0.27, p = 0.05), PaO2 (men:-0.59, p < 0.001), PaCO2 (men:0.27, p = 0.05), DLCO (men:-0.54, p < 0.001), P0.1/Pimax (men:0.46, p = 0.002; women:0.47, p = 0.005), dyspnea measured with the Visual Analog Scale before (men:0.37, p = 0.04; women:0.52, p = 0.004) and after 6MWD (men:0.52, p = 0.002; women:0.48, p = 0.004) and SGRQ total (men:0.50, p < 0.001; women:0.59, p < 0.001). Regression analysis showed that P0.1/Pimax in women (r2 = 0.30) and BMI, DLCO, PaO2 and P0.1/Pimax in men (r2 = 0.81) were the strongest predictors of MMRC scores. Conclusion In mild to severe COPD patients attending a pulmonary clinic, P0.1/Pimax was the unique predictor of MMRC scores only in women. Respiratory factors explain most of the variations of MMRC scores in men but not in women. Factors other than the respiratory ones should be included in the evaluation of dyspnea in women with COPD.
- Published
- 2007
- Full Text
- View/download PDF
114. Gender associated differences in determinants of quality of life in patients with COPD: a case series study
- Author
-
Montejo de Garcini Angela, Abreu Juan, Hernández Concepción, Casanova Ciro, de Torres Juan P, Aguirre-Jaime Armando, and Celli Bartolome R
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract Background The influence of gender on the expression of COPD has received limited attention. Quality of Life (QoL) has become an important outcome in COPD patients. The aim of our study was to explore factors contributing to gender differences in Quality of Life of COPD patients. Methods In 146 men and women with COPD from a pulmonary clinic we measured: Saint George's Respiratory Questionnaire (SGRQ), age, smoking history, PaO2, PaCO2, FEV1, FVC, IC/TLC, FRC, body mass index (BMI), 6 minute walk distance (6MWD), dyspnea (modified MRC), degree of comorbidity (Charlson index) and exacerbations in the previous year. We explored differences between genders using Mann-Whitney U-rank test. To investigate the main determinants of QoL, a multiple lineal regression analysis was performed using backward Wald's criteria, with those variables that significantly correlated with SGRQ total scores. Results Compared with men, women had worse scores in all domains of the SGRQ (total 38 vs 26, p = 0.01, symptoms 48 vs 39, p = 0.03, activity 53 vs 37, p = 0.02, impact 28 vs 15, p = 0.01). SGRQ total scores correlated in men with: FEV1% (-0.378, p < 0.001), IC/TLC (-0.368, p = 0.002), PaO2 (-0.379, p = 0.001), PaCO2 (0.256, p = 0.05), 6MWD (-0.327, p = 0.005), exacerbations (0.366, p = 0.001), Charlson index (0.380, p = 0.001) and MMRC (0.654, p < 0.001). In women, the scores correlated only with FEV1% (-0.293, p = 0.013) PaO2 (-0.315, p = 0.007), exacerbations (0.290, p = 0.013) and MMRC (0.628, p < 0.001). Regression analysis (B, 95% CI) showed that exercise capacity (0.05, 0.02 to 0.09), dyspnea (17.6, 13.4 to 21.8), IC/TLC (-51.1, -98.9 to -3.2) and comorbidity (1.7, 0.84 to 2.53) for men and dyspnea (9.7, 7.3 to 12.4) and oxygenation (-0.3, -0.6 to -0.01) for women manifested the highest independent associations with SGRQ scores. Conclusion In moderate to severe COPD patients attending a pulmonary clinic, there are gender differences in health status scores. In turn, the clinical and physiological variables independently associated with those scores differed in men and women. Attention should be paid to the determinants of QoL scores in women with COPD.
- Published
- 2006
- Full Text
- View/download PDF
115. Additional file 3: of Telomere shortening and accelerated aging in COPD: findings from the BODE cohort
- Author
-
Córdoba-Lanús, Elizabeth, Cazorla-Rivero, Sara, Espinoza-Jiménez, Adriana, De-Torres, Juan, Pajares, María J., Aguirre-Jaime, Armando, Celli, Bartolomé, and Casanova, Ciro
- Subjects
sense organs ,skin and connective tissue diseases - Abstract
Correlations between the rate of change in telomere length and the change in pulmonary function variables in patients with COPD after three years of follow-up. (DOCX 68 kb)
- Published
- 2017
- Full Text
- View/download PDF
116. Additional file 1: of Telomere shortening and accelerated aging in COPD: findings from the BODE cohort
- Author
-
Córdoba-Lanús, Elizabeth, Cazorla-Rivero, Sara, Espinoza-Jiménez, Adriana, De-Torres, Juan, Pajares, María J., Aguirre-Jaime, Armando, Celli, Bartolomé, and Casanova, Ciro
- Subjects
respiratory tract diseases - Abstract
Baseline characteristics of COPD patients with and without three-year follow-up included in the study. (DOCX 14 kb)
- Published
- 2017
- Full Text
- View/download PDF
117. Additional file 2: of Telomere shortening and accelerated aging in COPD: findings from the BODE cohort
- Author
-
Córdoba-Lanús, Elizabeth, Cazorla-Rivero, Sara, Espinoza-Jiménez, Adriana, De-Torres, Juan, Pajares, María J., Aguirre-Jaime, Armando, Celli, Bartolomé, and Casanova, Ciro
- Subjects
respiratory tract diseases - Abstract
Baseline characteristics of smokers without COPD with and without three-year follow-up included in the study. (DOCX 75 kb)
- Published
- 2017
- Full Text
- View/download PDF
118. A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future.
- Author
-
Llano, Luis Pérez de, Miravitlles, Marc, Golpe, Rafael, Alvarez-Gutiérrez, Francisco Javier, Cisneros, Carolina, Almonacid, Carlos, Martinez-Moragon, Eva, Gonzalez-Barcala, Francisco-Javier, Ramos-Barbón, David, Plaza, Vicente, Lopez-Campos, Jose Luis, de-Torres, Juan Pablo, Casanova, Ciro, Rivero, Juan Luis Garcia, Hermosa, Juan Rodriguez, Rubio, Myriam Calle, Soler-Cataluña, Juan Jose, and Cosio, Borja G
- Published
- 2020
- Full Text
- View/download PDF
119. Lung Cancer Screening Programs: a missed “window” to diagnose Obstructive Lung Disease. The NLST-ACRIN experience.
- Author
-
De Torres Tajes, Juan Pablo, primary, Wisnivesky, Juan, additional, Wilson, David, additional, Casanova, Ciro, additional, Marin, Jose María, additional, Pinto Plata, Victor, additional, Divo, Miguel, additional, Polverino, Francesca, additional, Cabrera, Carlos, additional, Zulueta, Javier, additional, Celli, Bartolome, additional, and Bastarrika, Gorka, additional
- Published
- 2018
- Full Text
- View/download PDF
120. Changes and Clinical Consequences of Smoking Cessation in Patients With COPD
- Author
-
Martínez-González, Cristina, primary, Casanova, Ciro, additional, de-Torres, Juan P., additional, Marín, José M., additional, de Lucas, Pilar, additional, Fuster, Antonia, additional, Cosío, Borja G., additional, Calle, Myriam, additional, Peces-Barba, Germán, additional, Solanes, Ingrid, additional, Agüero, Ramón, additional, Feu-Collado, Nuria, additional, Alfageme, Inmaculada, additional, Romero Plaza, Amparo, additional, Balcells, Eva, additional, de Diego, Alfredo, additional, Marín Royo, Margarita, additional, Moreno, Amalia, additional, Llunell Casanovas, Antonia, additional, Galdiz, Juan B., additional, Golpe, Rafael, additional, Lacárcel Bautista, Celia, additional, Cabrera, Carlos, additional, Marin, Alicia, additional, Soriano, Joan B., additional, and Lopez-Campos, Jose Luis, additional
- Published
- 2018
- Full Text
- View/download PDF
121. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco‐induced lung cancer
- Author
-
Fusco, Juan Pablo, primary, Pita, Guillermo, additional, Pajares, María José, additional, Andueza, Maria Pilar, additional, Patiño‐García, Ana, additional, de‐Torres, Juan P., additional, Gurpide, Alfonso, additional, Zulueta, Javier, additional, Alonso, Rosario, additional, Alvarez, Nuria, additional, Pio, Ruben, additional, Melero, Ignacio, additional, Sanmamed, Miguel F., additional, Rodriguez Ruiz, Maria, additional, Gil‐Bazo, Ignacio, additional, Lopez‐Picazo, Jose María, additional, Casanova, Ciro, additional, Baz Davila, Rebeca, additional, Agudo, Antonio, additional, Lozano, Maria Dolores, additional, Gonzalez, Alvaro, additional, Sala, Nuria, additional, Ardanaz, Eva, additional, Benitez, Javier, additional, Montuenga, Luis, additional, Gonzalez‐Neira, Anna, additional, and Perez‐Gracia, Jose Luis, additional
- Published
- 2018
- Full Text
- View/download PDF
122. Pulmonary arterial enlargement predicts long-term survival in COPD patients
- Author
-
de-Torres, Juan P., primary, Ezponda, Ana, additional, Alcaide, Ana B., additional, Campo, Arantza, additional, Berto, Juan, additional, Gonzalez, Jessica, additional, Zulueta, Javier J., additional, Casanova, Ciro, additional, Rodriguez-Delgado, Luisa Elena, additional, Celli, Bartolome R., additional, and Bastarrika, Gorka, additional
- Published
- 2018
- Full Text
- View/download PDF
123. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD
- Author
-
Casanova, Ciro, primary, Celli, Bartolome R., additional, de-Torres, Juan P., additional, Martínez-Gonzalez, Cristina, additional, Cosio, Borja G., additional, Pinto-Plata, Victor, additional, de Lucas-Ramos, Pilar, additional, Divo, Miguel, additional, Fuster, Antonia, additional, Peces-Barba, Germán, additional, Calle-Rubio, Myriam, additional, Solanes, Ingrid, additional, Aguero, Ramón, additional, Feu-Collado, Nuria, additional, Alfageme, Inmaculada, additional, De Diego, Alfredo, additional, Romero, Amparo, additional, Balcells, Eva, additional, Llunell, Antonia, additional, Galdiz, Juan B., additional, Marin, Margarita, additional, Moreno, Amalia, additional, Cabrera, Carlos, additional, Golpe, Rafael, additional, Lacarcel, Celia, additional, Soriano, Joan B., additional, López-Campos, José Luis, additional, Soler-Cataluña, Juan J., additional, and Marin, José M., additional
- Published
- 2017
- Full Text
- View/download PDF
124. A simple algorithm for the identification of clinical COPD phenotypes
- Author
-
Burgel, Pierre-Régis, primary, Paillasseur, Jean-Louis, additional, Janssens, Wim, additional, Piquet, Jacques, additional, ter Riet, Gerben, additional, Garcia-Aymerich, Judith, additional, Cosio, Borja, additional, Bakke, Per, additional, Puhan, Milo A., additional, Langhammer, Arnulf, additional, Alfageme, Inmaculada, additional, Almagro, Pere, additional, Ancochea, Julio, additional, Celli, Bartolome R., additional, Casanova, Ciro, additional, de-Torres, Juan P., additional, Decramer, Marc, additional, Echazarreta, Andrés, additional, Esteban, Cristobal, additional, Gomez Punter, Rosa Mar, additional, Han, MeiLan K., additional, Johannessen, Ane, additional, Kaiser, Bernhard, additional, Lamprecht, Bernd, additional, Lange, Peter, additional, Leivseth, Linda, additional, Marin, Jose M., additional, Martin, Francis, additional, Martinez-Camblor, Pablo, additional, Miravitlles, Marc, additional, Oga, Toru, additional, Sofia Ramírez, Ana, additional, Sin, Don D., additional, Sobradillo, Patricia, additional, Soler-Cataluña, Juan J., additional, Turner, Alice M., additional, Verdu Rivera, Francisco Javier, additional, Soriano, Joan B., additional, and Roche, Nicolas, additional
- Published
- 2017
- Full Text
- View/download PDF
125. The Impact of Emphysema on Chronic Obstructive Pulmonary Diseases
- Author
-
de Torres, Juan Pablo, primary and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
126. Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients
- Author
-
Zagaceta, Jorge, primary, Bastarrika, Gorka, additional, Zulueta, Javier J., additional, Colina, Inmaculada, additional, Alcaide, Ana B., additional, Campo, Arantza, additional, Divo, Miguel, additional, Casanova, Ciro, additional, Marin, José M., additional, Pinto-Plata, Victor M., additional, Celli, Bartolome R., additional, and de-Torres, Juan P., additional
- Published
- 2017
- Full Text
- View/download PDF
127. Telomere shortening and oxidative stress in patients with COPD
- Author
-
Cordoba Lanus, Aida Elizabeth, primary, Cazorla-Rivero, Sara, additional, Espinoza-Jimenez, Adriana, additional, Abreu, Pedro, additional, González-Almeida, Delia, additional, Aguirre-Jaime, Armando, additional, Celli, Bartolomé, additional, and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
128. Nocturnal hypoxaemia in COPD. Prevalence and clinical characteristics
- Author
-
Marin Trigo, Jose M., primary, Marin-Oto, Marta, additional, de Torres, Juan P, additional, Cabrera, Carlos, additional, Solanes, Ingrid, additional, Martinez, Cristina, additional, Toledo, Nuria, additional, Peces-Barba, German, additional, Amado, Carlos, additional, Vigil, Laura, additional, and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
129. Erratum to: Telomere shortening and accelerated aging in COPD: findings from the BODE cohort
- Author
-
Cordoba-Lanus, Elizabeth, primary, Cazorla-Rivero, Sara, additional, Espinoza-Jimenez, Adriana, additional, de-Torres, Juan P., additional, Pajares, María J., additional, Aguirre-Jaime, Armando, additional, Celli, Bartolomé, additional, and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
130. Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines
- Author
-
Miravitlles, Marc, primary, Alvarez-Gutierrez, Francisco Javier, additional, Calle, Myriam, additional, Casanova, Ciro, additional, Cosio, Borja G., additional, López-Viña, Antolín, additional, Pérez de Llano, Luis, additional, Quirce, Santiago, additional, Roman-Rodríguez, Miguel, additional, Soler-Cataluña, Juan José, additional, and Plaza, Vicente, additional
- Published
- 2017
- Full Text
- View/download PDF
131. Telomere shortening and accelerated aging in COPD: findings from the BODE cohort
- Author
-
Córdoba-Lanús, Elizabeth, primary, Cazorla-Rivero, Sara, additional, Espinoza-Jiménez, Adriana, additional, de-Torres, Juan P., additional, Pajares, María J., additional, Aguirre-Jaime, Armando, additional, Celli, Bartolomé, additional, and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
132. Chronic Obstructive Pulmonary Disease in Non-Smokers
- Author
-
Toledo-Pons, Nuria, primary, Cosío, Borja G., additional, Velasco, M. del Valle, additional, and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
133. Enfermedad pulmonar obstructiva crónica de origen no tabáquico
- Author
-
Toledo-Pons, Nuria, primary, Cosío, Borja G., additional, Velasco, M. del Valle, additional, and Casanova, Ciro, additional
- Published
- 2017
- Full Text
- View/download PDF
134. COPD heterogeneity: Gender differences in the multidimensional BODE index
- Author
-
de Torres, Juan P, Casanova, Ciro, de Garcini, Angela Montejo, Jaime, Armando Aguirre, and Celli, Bartolomé R
- Subjects
Male ,Age Factors ,Gender ,Walking ,Middle Aged ,Severity of Illness Index ,humanities ,Body Mass Index ,Pulmonary Disease, Chronic Obstructive ,Cross-Sectional Studies ,Sex Factors ,BODE index ,Forced Expiratory Volume ,COPD ,Humans ,Female ,Original Research ,Aged - Abstract
Background: The BODE index was recently validated as a multidimensional tool for the evaluation of patients with COPD. The influence of gender on the BODE index has not been studied. Hypothesis: The contribution of each component of the disease to the BODE index may differ according to gender. Methods: We evaluated age, forced expiratory volume in one second (FEV1), Modified Medical Research Council (MMRC) score, 6-min walk distance (6MWD), and body mass index (BMI) in 52 men and 52 women with COPD and the same BODE index. We compared the studied parameters between men and women and then performed a multiple regression analysis by gender. Results: We found statistically significant differences between men and women in all parameters: FEV1 % (55 ± 17 vs 63 ± 18, p < 0.001), MMRC [1 (0–2) vs 1 (1–2) p = 0.03], BMI [28 (26–30) vs 25 (22–30), p = 0.05], and 6MWD [546 (451–592) vs 462 (419–520), p = 0.001]. Multiple regression analysis revealed that each component of the BODE index had different weight (β standardized coefficient) in men and women respectively: FEV1% (0.74 vs 0.62), MMRC (0.31 vs 0.48), BMI (−0.09 vs −0.17), and 6MWD (0.13 vs 0.10). Conclusions: The contribution of each component to the BODE index differs by gender in subjects with similar BODE scores. Long term longitudinal studies will help determine the significance of our findings.
- Published
- 2007
135. What pulmonologists think about the asthma–COPD overlap syndrome
- Author
-
Miravitlles, Marc, Alcázar-Navarrete, Bernardino, Alvarez Gutiérrez, Francisco Javier, Bazús, Teresa, Calle Rubio, Myriam, Casanova, Ciro, Cisneros, Carolina, De Torres, Juan Pablo, Entrenas, Luis M., Esteban, Cristóbal, García-Sidro, Patricia, Cosio, Borja G.., Huerta, Arturo, Iriberri, Milagros, Izquierdo, José Luis, López Viña, Antolín, López-Campos, José Luis, Martínez-Moragón, Eva, Pérez de Llano, Luis, Perpiñá, Miguel, Ros, José Antonio, Serrano, José, Soler-Cataluña, Juan José, Torrego, Alfons, Urrutia, Isabel, Plaza, Vicente, Universitat Autònoma de Barcelona, [Miravitlles,M] Pneumology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain. [Miravitlles,M, López-Campos,L] CIBER de Enfermedades Respiratorias (CIBERES) Madrid, Spain. [Alcázar,B] Respiratory Department, Hospital de Alta Resolución de Loja, Granada, Spain. [Alvarez,FJ, López-Campos,L] Medical-Surgical Unit of Respiratory Diseases, Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IbiS), Seville, Spain. [Bazús,T] Department of Pneumology, Hospital Universitario Central de Asturias, Ovido, Spain. [Calle,M] Department of Pneumology, Hospital Clínico San Carlos, Madrid, Spain. [Casanova,C] Department of Pneumology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain. [Cisneros,C] Department of Pneumology, Hospital Universitario de La Princesa/Instituto de Investigación Sanitaria (IIS-IP), Madrid, Spain. [De Torres,JP] Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain. [Entrenas,LM] Department of Pneumology, Hospital Universitario Reina Sofía, Córdoba, Spain. [Esteban,C, Urrutia,I] Department of Pneumology, Hospital Galdakao-Usansolo, Galdakao, Spain. [García-Sidro,P] Department of Pneumology, Hospital Universitario de La Plana, Vila-Real, Spain. [Cosio,BC] Department of Pneumology, Hospital Universitario Son Espases IdISPa, Palma de Mallorca, Spain. [Huerta,A] Sección Urgencias Medicina - Neumología, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Spain. [Iriberri,M] Department of Pneumology, Hospital Universitario de Cruces, Bilbao, Spain. [Izquierdo,JL] Department of Pneumology, Hospital Universitario de Guadalajara, Guadalajara, Spain. [López-Viña,A] Department of Pneumology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain. [Martínez-Moragón,E] Department of Pneumology, Hospital Universitario Dr. Peset, Valencia, Spain. [Pérez de Llano,L] Department of Pneumology, Hospital Universitario Lucus Augusti, Lugo, Spain. [Perpiñá,M] Department of Pneumology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Ros,JA] Department of Pneumology, Hospital Clínico Universitario Virgen de la Arrinxaca, Murcia, Spain. [Serrano,J] Department of Pneumology, Hospital Comarcal de Inca, Inca, Spain. [Soler-Cataluña,JJ] Department of Pneumology, Hospital Arnau de Vilanova-Liria, Valencia, Spain. [Torrejo,A, Plaza,V] Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., and Marc Miravitlles has received speaker fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, Esteve, GlaxoSmithKline, Menarini, Grifols, and Novartis, and consulting fees from Almirall, Boehringer Ingelheim, Cipla, Pfizer, GlaxoSmithKline, Gebro Pharma, CLS Behring, MediImmune, Takeda, Teva, Novartis, and Grifols. Bernardino Alcázar reports personal fees from Novartis AG, Boehringer Ingelheim, GSK, Almirall, AstraZeneca, and grants and personal fees from Menarini. Teresa Bazús has received honoraria or funding for attending scientific meetings from GSK, Chiesi, and Teva. Ciro Casanova has received speaker fees from AstraZeneca, GSK, Novartis, and Almirall y Gebro Pharma and consulting fees from Almirall, Novartis, and GSK. Carolina Cisneros has received speaker or consulting fees from AstraZeneca, GSK, Boehringer Ingelheim, Novartis, Takeda, Vifor Pharma, Chiesi, Orion, and Mundipharma. Luis M Entrenas has in the last 3 years received honoraria for speaking at sponsored meetings from Alter, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Menarini, MSD, Mundipharma, Novartis, Pfizer, and Teva, as a consultant for Chiesi, Mundipharma, and Novartis, and has received funding/grant support for research projects from not-for-profit foundations, as well as Novartis. Patricia García-Sidro has received fees for scientific meetings, scientific advice, and participating in clinical studies or writing for publications from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, Gebro, GlaxoSmithKline, Menarini, MSD, Mundipharma, Novartis, Pfizer, Rovi, Takeda-Nycomed, and Teva. Borja G Cosio has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer, consultant fees from Pfizer, Chiesi, and GSK, travel grants from Boehringer Ingelheim, Novartis, and Chiesi, and received unrestricted funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Boehringer Ingelheim, Chiesi, and Menarini. Arturo Huerta has received personal fees from GSK, Novartis, Takeda, Menarini, and Boehringer Ingelheim. José Luis Izquierdo reports personal fees for consulting and lectures from Almirall, AstraZeneca, Bayer, Boehringer Ingelheim, Takeda-Nycomed, Pfizer, and Menarini. Antolin López-Viña has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer, as a consultant for Pfizer, Boehringer Ingelheim, and Novartis, has received assistance to meet travel costs from Boehringer Ingelheim, Novartis, Teva, and Chiesi, and has received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi and Menarini. Eva Martínez-Moragón has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Teva, and Pfizer. Luis Pérez de Llano has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Menarini, Chiesi, GlaxoSmithKline, Teva, Almirall, Mundipharma, Esteve, Novartis, and Pfizer, as a consultant for Mundipharma, Pfizer, Ferrer, and Novartis, has received assistance to meet travel costs from GSK and Novartis, and has received funding/grant support for research projects from SEPAR and SERGAS. Juan José Soler-Cataluña has received speaker fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Merck, Menarini, Sharp & Dohme, Novartis, Takeda, and Pfizer, and consulting fees from Boehringer Ingelheim, GSK, AstraZeneca, Ferrer, Novartis, Almirall, Merck, Sharp & Dohme, and Takeda. Vicente Plaza has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, and Pfizer, as a consultant for Mundipharma, Orion and Teva, received assistance to meet travel costs from Boehringer Ingelheim and Chiesi, and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi, Menarini, and Merck. The authors report no other conflicts of interest in this work.
- Subjects
Male ,Health Knowledge, Attitudes, Practice ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Questionnaires [Medical Subject Headings] ,humanos ,Disciplines and Occupations::Health Occupations::Specialization [Medical Subject Headings] ,Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,broncodilatadores ,Anti-asthmatic Agent ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Pulmonary Disease, Chronic Obstructive ,Adrenal Cortex Hormones ,Risk Factors ,immune system diseases ,Surveys and Questionnaires ,Pulmonary medicine ,Pulmonary Medicine ,Enfermedad pulmonar obstructiva crónica ,Anti-Asthmatic Agents ,guidelines ,mediana edad ,Pulmonologists ,Original Research ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,COPD ,education.field_of_study ,Smoking ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Respiratory System Agents::Anti-Asthmatic Agents::Bronchodilator Agents [Medical Subject Headings] ,Overlap syndrome ,General Medicine ,Middle Aged ,Prognosis ,actitud del personal sanitario ,consenso ,Bronchodilator Agents ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings] ,asma ,pronóstico ,Consenso ,Female ,Antiasmáticos ,antiasmáticos ,Specialization ,medicine.medical_specialty ,Consensus ,Attitude of Health Personnel ,Population ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings] ,Check Tags::Male [Medical Subject Headings] ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Respiratory System Agents::Anti-Asthmatic Agents [Medical Subject Headings] ,Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Asthma [Medical Subject Headings] ,International Journal of Chronic Obstructive Pulmonary Disease ,Predictive Value of Tests ,medicine ,Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive [Medical Subject Headings] ,Humans ,factores de riesgo ,especialización ,survey ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Research Design::Sensitivity and Specificity::Predictive Value of Tests [Medical Subject Headings] ,Asthma copd overlap ,Intensive care medicine ,education ,Adrenergic beta-2 Receptor Agonists ,Asma ,Corticoesteroides ,Asthma ,pruebas de valores predictivos ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus [Medical Subject Headings] ,business.industry ,Disciplines and Occupations::Health Occupations::Medicine::Internal Medicine::Pulmonary Medicine [Medical Subject Headings] ,Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones [Medical Subject Headings] ,hábito de fumar ,asthma ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Agonists::Adrenergic beta-Agonists::Adrenergic beta-2 Receptor Agonists [Medical Subject Headings] ,medicine.disease ,agonistas de receptores adrenérgicos beta-2 ,Broncodilatadores ,Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care::Attitude to Health::Health Knowledge, Attitudes, Practice [Medical Subject Headings] ,respiratory tract diseases ,medicina pulmonar ,Check Tags::Female [Medical Subject Headings] ,Spain ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Attitude::Attitude of Health Personnel [Medical Subject Headings] ,Physical therapy ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings] ,business ,hormonas de la corteza suprarrenal ,ACOS - Abstract
Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma-COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity,0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting beta(2)-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting beta(2)-agonist/inhaled corticosteroids., The authors want to thank Montserrat Falgueras, Maria Fontanals, Laura Molina, Rosa Palomino, and Sonia Pisa (GOC Networking, Barcelona, Spain) for their help in the organization of the study, data entry and analysis of the questionnaires, and the facilitation of the Metaplan session. This study was funded by Chiesi Spain.
- Published
- 2015
136. External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study.
- Author
-
Almagro, Pere, Martínez-Camblor, Pablo, Miravitlles, Marc, Rodríguez-Carballeira, Mónica, Navarro, Annie, Lamprecht, Bernd, Ramirez-Garcia Luna, Ana S, Kaiser, Bernhard, Alfageme, Inmaculada, Casanova, Ciro, Esteban, Cristobal, Soler-Cataluña, Juan J, de-Torres, Juan P, Celli, Bartolome R, Marin, Jose M, ter Riet, Gerben, Sobradillo, Patricia, Lange, Peter, Garcia-Aymerich, Judith, and Anto, Josep M
- Subjects
MANUSCRIPTS ,PROPORTIONAL hazards models ,COHORT analysis ,RECEIVER operating characteristic curves - Abstract
The CODEX index was developed and validated in patients hospitalized for COPD exacerbation to predict the risk of death and readmission within one year after discharge. Our study aimed to validate the CODEX index in a large external population of COPD patients with variable durations of follow-up. Additionally, we aimed to recalculate the thresholds of the CODEX index using the cutoffs of variables previously suggested in the 3CIA study (mCODEX). Individual data on 2,755 patients included in the COPD Cohorts Collaborative International Assessment Plus (3CIA+) were explored. A further two cohorts (ESMI AND EGARPOC-2) were added. To validate the CODEX index, the relationship between mortality and the CODEX index was assessed using cumulative/dynamic ROC curves at different follow-up periods, ranging from 3 months up to 10 years. Calibration was performed using univariate and multivariate Cox proportional hazard models and Hosmer-Lemeshow test. A total of 3,321 (87.8% males) patients were included with a mean ± SD age of 66.9 ± 10.5 years, and a median follow-up of 1,064 days (IQR 25–75% 426–1643), totaling 11,190 person-years. The CODEX index was statistically associated with mortality in the short- (≤3 months), medium- (≤1 year) and long-term (10 years), with an area under the curve of 0.72, 0.70 and 0.76, respectively. The mCODEX index performed better in the medium-term (<1 year) than the original CODEX, and similarly in the long-term. In conclusion, CODEX and mCODEX index are good predictors of mortality in patients with COPD, regardless of disease severity or duration of follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
137. Long-term Controlled Trial of Nocturnal Nasal Positive Pressure Ventilation in Patients With Severe COPD
- Author
-
Casanova, Ciro
- Subjects
Lung diseases, Obstructive -- Care and treatment ,Positive pressure respiration -- Evaluation - Published
- 2001
138. Identification of clinical phenotypes in patients with and without COPD using cluster analysis
- Author
-
Divo, Miguel, primary, Casanova, Ciro, additional, Marin, Jose M., additional, Celli, Bartolome, additional, de Torres, Juan Pablo, additional, Polverino, Francesca, additional, Baz, Rebeca, additional, Cordoba-Lanus, Elizabeth, additional, and Pinto-Plata, Victor, additional
- Published
- 2016
- Full Text
- View/download PDF
139. Beta-blockers and COPD: the show must go on
- Author
-
Lopez-Campos, Jose Luis, primary, Márquez-Martín, Eduardo, additional, and Casanova, Ciro, additional
- Published
- 2016
- Full Text
- View/download PDF
140. Role of HIF1A, VEGFA and VEGFR2 SNPs in the Susceptibility and Progression of COPD in a Spanish Population
- Author
-
Baz-Dávila, Rebeca, primary, Espinoza-Jiménez, Adriana, additional, Rodríguez-Pérez, María del Cristo, additional, Zulueta, Javier, additional, Varo, Nerea, additional, Montejo, Ángela, additional, Almeida-González, Delia, additional, Aguirre-Jaime, Armando, additional, Córdoba-Lanús, Elizabeth, additional, and Casanova, Ciro, additional
- Published
- 2016
- Full Text
- View/download PDF
141. Is COPD a Progressive Disease? A Long Term Bode Cohort Observation
- Author
-
de-Torres, Juan P., primary, Marín, Jose M., additional, Pinto-Plata, Víctor, additional, Divo, Miguel, additional, Sanchez-Salcedo, Pablo, additional, Zagaceta, Jorge, additional, Zulueta, Javier J., additional, Berto, Juan, additional, Cabrera, Carlos, additional, Celli, Bartolome R., additional, and Casanova, Ciro, additional
- Published
- 2016
- Full Text
- View/download PDF
142. Simplifying the Guidelines: The 10 COPD Commandments
- Author
-
Marin, José María, primary, Cote, Claudia, additional, Casanova, Ciro, additional, Pinto-Plata, Victor, additional, Montes de Oca, María, additional, Divo, Miguel J, additional, de Torres, Juan P, additional, Zulueta, Javier, additional, Cabrera, Carlos, additional, Carrizo, Santiago, additional, Polverino, Francesca, additional, and Celli, Bartolomé R, additional
- Published
- 2016
- Full Text
- View/download PDF
143. Simplificando las guías: los 10 mandamientos de la EPOC
- Author
-
Marin, José María, primary, Cote, Claudia, additional, Casanova, Ciro, additional, Pinto-Plata, Victor, additional, Montes de Oca, María, additional, Divo, Miguel J, additional, de Torres, Juan P, additional, Zulueta, Javier, additional, Cabrera, Carlos, additional, Carrizo, Santiago, additional, Polverino, Francesca, additional, and Celli, Bartolomé R, additional
- Published
- 2016
- Full Text
- View/download PDF
144. The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study.
- Author
-
de Torres, Juan P., Marin, Jose M., Martinez‐Gonzalez, Cristina, de Lucas‐Ramos, Pilar, Cosio, Borja, Casanova, Ciro, and for the COPD History Assessment In SpaiN (CHAIN) cohort
- Subjects
OBSTRUCTIVE lung diseases patients ,CLUSTER analysis (Statistics) ,PHENOTYPES ,PULMONARY function tests ,QUALITY of life - Abstract
Abstract: Background and objective: Cluster analysis has been utilized to explore phenotypic heterogeneity in chronic obstructive pulmonary disease (COPD). To date, little is known about the longitudinal variability of clusters in COPD patients. We aimed to evaluate the 2‐year cluster variability in stable COPD patients. Methods: We evaluated the following variables in COPD patients at baseline and 2 years later: age, gender, pack‐year history, body mass index (BMI), modified Medical Research Council (MMRC) scale, 6‐min walking distance (6MWD), spirometry and COPD Assessment Test (CAT). Patient classification was performed using cluster analysis at baseline and 2 years later. Each patient’s cluster variability after 2 years and its parameters associated with cluster change were explored. Results: A total of 521 smokers with COPD were evaluated at baseline and 2 years later. Three different clusters were consistently identified at both evaluation times: cluster A (of younger age, mild airway limitation, few symptoms), cluster B (intermediate) and cluster C (of older age, severe airway limitation and highly symptomatic). Two years later, 70% of patients were unchanged, whereas 30% changed from one cluster to another: 20% from A to B; 15% from B to A; 15% from B to C; 42% from C to B and 8% from C to A. 6MWD, forced expiratory volume in 1 s (FEV
1 ) % and CAT were the principal parameters responsible for this change. Conclusion: After 2 years of follow‐up, most of the COPD patients maintained their cluster assignment. Exercise tolerance, lung function and quality of life were the main driving parameters in those who change their cluster assignment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
145. Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort.
- Author
-
Divo, Miguel J., Celli, Bartolome R., Poblador-Plou, Beatriz, Calderón-Larrañaga, Amaia, de-Torres, Juan Pablo, Gimeno-Feliu, Luis A., Bertó, Juan, Zulueta, Javier J., Casanova, Ciro, Pinto-Plata, Victor M., Cabrera-Lopez, Carlos, Polverino, Francesca, Carmona Píréz, Jonás, Prados-Torres, Alexandra, Marin, Jose M., and null, null
- Subjects
AGING ,CHRONIC diseases ,OBSTRUCTIVE lung diseases ,COMORBIDITY ,SMOKING - Abstract
Background: Aging is an important risk factor for most chronic diseases. Patients with COPD develop more comorbidities than non-COPD subjects. We hypothesized that the development of comorbidities characteristically affecting the elderly occur at an earlier age in subjects with the diagnosis of COPD. Methods and findings: We included all subjects carrying the diagnosis of COPD (n = 27,617), and a similar number of age and sex matched individuals without the diagnosis, extracted from the 727,241 records of individuals 40 years and older included in the EpiChron Cohort (Aragon, Spain). We compared the cumulative number of comorbidities, their prevalence and the mortality risk between both groups. Using network analysis, we explored the connectivity between comorbidities and the most influential comorbidities in both groups. We divided the groups into 5 incremental age categories and compared their comorbidity networks. We then selected those comorbidities known to affect primarily the elderly and compared their prevalence across the 5 age groups. In addition, we replicated the analysis in the smokers’ subgroup to correct for the confounding effect of cigarette smoking. Subjects with COPD had more comorbidities and died at a younger age compared to controls. Comparison of both cohorts across 5 incremental age groups showed that the number of comorbidities, the prevalence of diseases characteristic of aging and network’s density for the COPD group aged 56–65 were similar to those of non-COPD 15 to 20 years older. The findings persisted after adjusting for smoking. Conclusion: Multimorbidity increases with age but in patients carrying the diagnosis of COPD, these comorbidities are seen at an earlier age. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
146. Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease.
- Author
-
Riesco Miranda, Juan Antonio, Alcázar, Bernardino, Alfageme, Inmaculada, Casanova, Ciro, Celli, Bartolomé, de-Torres, Juan P., and Jiménez Ruiz, Carlos A.
- Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
147. COPD comorbidities network
- Author
-
Divo, Miguel J., primary, Casanova, Ciro, additional, Marin, Jose M., additional, Pinto-Plata, Victor M., additional, de-Torres, Juan P., additional, Zulueta, Javier J., additional, Cabrera, Carlos, additional, Zagaceta, Jorge, additional, Sanchez-Salcedo, Pablo, additional, Berto, Juan, additional, Davila, Rebeca Baz, additional, Alcaide, Ana B., additional, Cote, Claudia, additional, and Celli, Bartolome R., additional
- Published
- 2015
- Full Text
- View/download PDF
148. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data
- Author
-
Soriano, Joan B, primary, Lamprecht, Bernd, additional, Ramírez, Ana S, additional, Martinez-Camblor, Pablo, additional, Kaiser, Bernhard, additional, Alfageme, Inmaculada, additional, Almagro, Pere, additional, Casanova, Ciro, additional, Esteban, Cristobal, additional, Soler-Cataluña, Juan J, additional, de-Torres, Juan P, additional, Miravitlles, Marc, additional, Celli, Bartolome R, additional, Marin, Jose M, additional, Puhan, Milo A, additional, Sobradillo, Patricia, additional, Lange, Peter, additional, Sternberg, Alice L, additional, Garcia-Aymerich, Judith, additional, Turner, Alice M, additional, Han, MeiLan K, additional, Langhammer, Arnulf, additional, Leivseth, Linda, additional, Bakke, Per, additional, Johannessen, Ane, additional, Roche, Nicolas, additional, and Sin, Don D, additional
- Published
- 2015
- Full Text
- View/download PDF
149. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD
- Author
-
Celli, Bartolome R., primary, Decramer, Marc, additional, Wedzicha, Jadwiga A., additional, Wilson, Kevin C., additional, Agustí, Alvar A., additional, Criner, Gerard J., additional, MacNee, William, additional, Make, Barry J., additional, Rennard, Stephen I., additional, Stockley, Robert A., additional, Vogelmeier, Claus, additional, Anzueto, Antonio, additional, Au, David H., additional, Barnes, Peter J., additional, Burgel, Pierre-Regis, additional, Calverley, Peter M., additional, Casanova, Ciro, additional, Clini, Enrico M., additional, Cooper, Christopher B., additional, Coxson, Harvey O., additional, Dusser, Daniel J., additional, Fabbri, Leonardo M., additional, Fahy, Bonnie, additional, Ferguson, Gary T., additional, Fisher, Andrew, additional, Fletcher, Monica J., additional, Hayot, Maurice, additional, Hurst, John R., additional, Jones, Paul W., additional, Mahler, Donald A., additional, Maltais, François, additional, Mannino, David M., additional, Martinez, Fernando J., additional, Miravitlles, Marc, additional, Meek, Paula M., additional, Papi, Alberto, additional, Rabe, Klaus F., additional, Roche, Nicolas, additional, Sciurba, Frank C., additional, Sethi, Sanjay, additional, Siafakas, Nikos, additional, Sin, Don D., additional, Soriano, Joan B., additional, Stoller, James K., additional, Tashkin, Donald P., additional, Troosters, Thierry, additional, Verleden, Geert M., additional, Verschakelen, Johny, additional, Vestbo, Jorgen, additional, Walsh, John W., additional, Washko, George R., additional, Wise, Robert A., additional, Wouters, Emiel F.M., additional, and ZuWallack, Richard L., additional
- Published
- 2015
- Full Text
- View/download PDF
150. Association between the presence of the Panton-Valentine leukocidin-encoding gene and a lower rate of survival among hospitalized pulmonary patients with staphylococcal disease
- Author
-
López-Aguilar, Celeste, Pérez-Roth, Eduardo, Méndez-Álvarez, Sebastián, Alcoba-Flórez, Julia, Moreno, Antonio M., Durán, Manuel C., Casanova, Ciro, Aguirre-Jaíme, Armando J., and Instituto de Salud Carlos III
- Subjects
Male ,Microbiology (medical) ,Staphylococcus aureus ,Pathology ,medicine.medical_specialty ,Bacterial toxins ,Exotoxins ,Disease ,Staphylococcal infections ,medicine.disease_cause ,Microbiology ,Leukocidins ,Pneumonia, Staphylococcal ,medicine ,Humans ,Letters to the Editor ,Gene ,Survival analysis ,Aged ,Aged, 80 and over ,biology ,business.industry ,Middle Aged ,Staphylococcal Infections ,medicine.disease ,biology.organism_classification ,Survival Analysis ,respiratory tract diseases ,Hospitalization ,Pneumonia ,Spain ,Female ,Methicillin Resistance ,Panton–Valentine leukocidin ,business ,Bacteria - Abstract
4 pag.- 1 fig.- 2 tab., Staphylococcus aureus is responsible for more than 2% of cases of communityacquired pneumonia and 10% of cases of nosocomial-acquired pneumonia. The lethality rate of such infections ranges from 30% to 80%. These infections are complicated by the fact that these bacteria have acquired diverse genetic information that makes them resistant to most antibiotics. Methicillin-resistant S. aureus (MRSA) is the most common cause of serious hospital-acquired infections (1). Infections of the respiratory tract by S. aureus can be more severe if the infecting strain produces the Panton-Valentine leukocidin (PVL) (11). The serious impact of PVL positive S. aureus infections seems to be associated with pulmonary complications., We are grateful to J.P. de Torres for critical reading of the manuscript. The study was partially supported by grants FUNCIS 02/38 and MEC BIO2002/00953, Spain, to S.M.A. S.M.A. was partially supported by Public Health Research Foundation (FIS) grant 99/3060, Spain. E.P.R. and C.L.A. were partially supported by grants from Consejería de Educación, Cultura y Deportes and FUNCIS, respectively, Gobierno de Canarias Autonomous Government, Spain.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.